PATH | VRL
Menu

Re-Evaluating the Cost and Cost-Effectiveness of Rotavirus Vaccination in Bangladesh, Ghana, and Malawi: A Comparison of Three Rotavirus Vaccines

This article, published in Vaccine, reports the results of a cost and cost-effectiveness analysis of rotavirus vaccination in Bangladesh, Ghana, and Malawi to compare the economic impacts of three vaccines―Rotarix®, ROTAVAC®, and ROTASIIL®. Rotarix has already been introduced in a number of countries supported by Gavi, the Vaccine Alliance. ROTAVAC and ROTASIIL have recently been prequalified by the World Health Organization and are now available for global use, including Gavi-eligible countries. The authors concluded that each of the vaccine products is projected to be highly cost-effective relative to no vaccination, and the article provides health economic evidence that may help inform vaccine choice alongside a number of other factors.

Author: Pecenka C, Debellut F, Bar-Zeev N, et al.

Published: 2018

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Pecenka C, Debellut F, Bar-Zeev N, et al. Re-Evaluating the Cost and Cost-Effectiveness of Rotavirus Vaccination in Bangladesh, Ghana, and Malawi: A Comparison of Three Rotavirus Vaccines. Vaccine. 2018;36(49):7472-7478.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Immunization financing, Disease/vaccine specific information

Regions: Africa, Asia